AR073158A1 - Metodo y composicion para modular el crecimiento de celulas madre - Google Patents

Metodo y composicion para modular el crecimiento de celulas madre

Info

Publication number
AR073158A1
AR073158A1 ARP090100582A ARP090100582A AR073158A1 AR 073158 A1 AR073158 A1 AR 073158A1 AR P090100582 A ARP090100582 A AR P090100582A AR P090100582 A ARP090100582 A AR P090100582A AR 073158 A1 AR073158 A1 AR 073158A1
Authority
AR
Argentina
Prior art keywords
hydroxy
composition
modulate
cycloalkyl
stem cells
Prior art date
Application number
ARP090100582A
Other languages
English (en)
Spanish (es)
Inventor
Sachiko Kuno
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR073158A1 publication Critical patent/AR073158A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP090100582A 2008-02-19 2009-02-19 Metodo y composicion para modular el crecimiento de celulas madre AR073158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2971308P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
AR073158A1 true AR073158A1 (es) 2010-10-20

Family

ID=40602552

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100582A AR073158A1 (es) 2008-02-19 2009-02-19 Metodo y composicion para modular el crecimiento de celulas madre

Country Status (16)

Country Link
US (2) US8871752B2 (https=)
EP (2) EP2303278A1 (https=)
JP (1) JP2011512323A (https=)
KR (1) KR20100119803A (https=)
CN (2) CN104248638A (https=)
AR (1) AR073158A1 (https=)
AU (1) AU2009216067B2 (https=)
BR (1) BRPI0907831A2 (https=)
CA (1) CA2715486A1 (https=)
IL (1) IL207652A0 (https=)
MX (1) MX2010009131A (https=)
NZ (1) NZ587348A (https=)
RU (1) RU2010138603A (https=)
TW (1) TW200942614A (https=)
WO (1) WO2009104807A1 (https=)
ZA (1) ZA201006125B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108028A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
EP2435049A1 (en) * 2009-05-27 2012-04-04 Sucampo AG Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders
KR101171912B1 (ko) 2010-11-29 2012-08-07 기아자동차주식회사 밸브브릿지 일체형 가변 밸브 액츄에이터
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス,インコーポレイテッド 増強された幹細胞組成物
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US20140371304A1 (en) * 2013-06-13 2014-12-18 Sucampo Ag Method for suppressing tumorigenicity of stem cells
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
JP2019513010A (ja) * 2016-03-04 2019-05-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー プロスタグランジンe2を用いる、筋再生のための組成物および方法
WO2018227138A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
EP0503887B1 (en) * 1991-03-14 1996-08-28 R-Tech Ueno Ltd. Promotion of wound-healing with 15-keto-prostaglandin compounds
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
JP3187438B2 (ja) * 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
EP1267882B1 (en) 2000-03-24 2009-04-15 Sucampo AG Prostaglandins for the treatment of eye disease caused by light irradiation like photoretinitis
DK1841433T3 (da) 2005-01-27 2012-01-16 Sucampo Ag Præparat til behandling af lidelser i centralnervesystemet
JP4557288B2 (ja) * 2005-01-28 2010-10-06 アイシン・エィ・ダブリュ株式会社 画像認識装置及び画像認識方法、並びにそれを用いた位置特定装置、車両制御装置及びナビゲーション装置
DE602006018583D1 (de) * 2005-03-04 2011-01-13 Sucampo Ag Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
AU2006326853B2 (en) 2005-12-22 2012-02-16 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
EP2114411A2 (en) * 2007-02-27 2009-11-11 Sucampo AG Composition and method for protecting mitochondria
FI20075417A0 (fi) * 2007-06-05 2007-06-05 Marjo-Riitta Suuronen Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen

Also Published As

Publication number Publication date
US20090209643A1 (en) 2009-08-20
CN102014921A (zh) 2011-04-13
AU2009216067B2 (en) 2014-02-13
TW200942614A (en) 2009-10-16
WO2009104807A1 (en) 2009-08-27
NZ587348A (en) 2012-04-27
ZA201006125B (en) 2011-05-25
CA2715486A1 (en) 2009-08-27
IL207652A0 (en) 2010-12-30
BRPI0907831A2 (pt) 2017-04-11
US8871752B2 (en) 2014-10-28
EP2303278A1 (en) 2011-04-06
RU2010138603A (ru) 2012-03-27
US20150005381A1 (en) 2015-01-01
CN104248638A (zh) 2014-12-31
KR20100119803A (ko) 2010-11-10
JP2011512323A (ja) 2011-04-21
AU2009216067A1 (en) 2009-08-27
MX2010009131A (es) 2010-12-06
EP2656845A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
AR073158A1 (es) Metodo y composicion para modular el crecimiento de celulas madre
PE20130155A1 (es) Derivados de ariletinilo
CO6220952A2 (es) Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
UY27227A1 (es) Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad
AR072657A1 (es) Compuestos inhibidores de raf y metodos para su uso
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR065093A1 (es) Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
AR111812A2 (es) Compuestos y composiciones para el control de nematodos
EA201390879A1 (ru) Трициклические ингибиторы pi3k и способы их применения
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR069596A1 (es) Regulador del crecimiento de plantas
CO6341575A2 (es) Combinaciones que comprenden metotrexato e inhibidores de dhodh
ES2613538T3 (es) Derivados de arilamida como bloqueadores de TTX-S
CO6400139A2 (es) Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica
MX2018013175A (es) Metodo de purificacion para celulas precursoras pancreaticas derivadas a partir de celulas madre pluripotentes y metodo de amplificacion para ellas.
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR079498A1 (es) Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a
CO6460743A2 (es) Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR068367A1 (es) Derivados de amidas con actividad fungicida
AR057350A1 (es) Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure